![]() ![]() ![]() One hundred thirty-five patients had bidimensionally measurable disease, and 27 patients had assessable disease. One hundred sixty-three patients were entered onto the study at 25 centers, and 162 patients received capecitabine. PATIENTS AND METHODS: Patients were to have received at least two but not more than three prior chemotherapeutic regimens, one of which had to have contained paclitaxel given for metastatic disease. ![]() This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m 2/d given for 2 weeks followed by a 1-week rest period and repeated in 3-week cycles, in patients with paclitaxel-refractory metastatic breast cancer. PURPOSE: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |